SLC6A21P

Across TCGA pan-cancer cohorts, SLC6A21P RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated SLC6A21P data layer.

The strongest signal is observed in mesothelioma (MESO), where higher SLC6A21P RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC6A21P expression acts as an unfavorable survival marker, although some lineages such as MESO and UCS show a favorable association.

MESO, UCS, and PRAD are the cancer types where SLC6A21P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	II,III,IV	0.711	0.254	.001	45	view →
UCS	DFS	Median	III,IV	0.527	0.138	.001	36	view →
PRAD	DFS	Quartile	All	0.808	0.940	<.001	28	view →
THCA	DFS	Tertile	All	0.789	0.937	.001	27	view →
ACC	OS	Tertile	II,III,IV	0.565	0.924	.001	25	view →
HNSC	OS	Median	All	0.826	0.728	.009	22	view →
STAD	DFS	Median	III,IV	0.518	0.195	.014	19	view →
BLCA	OS	Tertile	III,IV	0.641	0.500	.018	12	view →
LUAD	DFS	Median	All	0.460	0.291	.006	11	view →
LGG	OS	Tertile	All	0.323	0.514	.015	11	view →
KIRP	OS	Tertile	All	0.598	0.780	.016	7	view →
GBM	OS	Median	All	0.495	0.370	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

SLC6A21P–MESO (DFS)

Open the MESO breakdown →